Mesoblast Limited

Contributing Author

Recent Articles by Mesoblast Limited

Apr-14	Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products MESO +7.80% GlobeNewswire
Apr-10	Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy - CORRECTION MESO GlobeNewswire
Apr-08	Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation MESO GlobeNewswire
Apr-07	Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy MESO GlobeNewswire
Apr-06	Ryoncil Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter MESO -7.97% GlobeNewswire
Mar-17	Mesoblast to Host R&D Day on April 8, 2026 MESO GlobeNewswire
Mar-11	Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast MESO GlobeNewswire
Feb-26	Ryoncil Profits Underpinning Substantial Growth Pipeline MESO -6.32% GlobeNewswire
Feb-20	Mesoblast Financial Results and Corporate Update Webcast MESO GlobeNewswire
Feb-11	High Survival Rates With Ryoncil in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD MESO -7.70% MESO GlobeNewswire
Jan-28	Ryoncil Net Revenues Increase for the Quarter to US$30M MESO GlobeNewswire
Jan-26	Real-World Commercial Experience with Ryoncil Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment MESO GlobeNewswire
Jan-18	FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy MESO GlobeNewswire
Jan-08	Ryoncil Sales Increase 60% in December Quarter to US$35.1M MESO +5.49% MESO GlobeNewswire
Jan-01	Mesoblast Announces Changes to Board of Directors' Leadership Roles MESO GlobeNewswire
Dec-29	Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line MESO GlobeNewswire
Dec-11	Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD MESO GlobeNewswire
Dec-03	Mesoblast Participation at Piper Sandler Conference MESO GlobeNewswire
Nov-24	Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil Revenue MESO GlobeNewswire
Nov-20	Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids MESO +7.33% MESO GlobeNewswire
Nov-17	James M. O'Brien Appointed Chief Financial Officer at Mesoblast MESO GlobeNewswire
Nov-04	Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation MESO GlobeNewswire
Oct-19	Ryoncil Net Revenues Increase 69% in Second Quarter Post Launch MESO GlobeNewswire
Oct-06	Ryoncil Revenues Increase 66% in Second Quarter Post Launch MESO -5.92% GlobeNewswire
Oct-02	Ryoncil Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access MESO +8.17% GlobeNewswire
Sep-26	Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs MESO GlobeNewswire
Sep-14	Successful Commercial Launch of Ryoncil Highlighted at Global Healthcare Conferences MESO GlobeNewswire
Sep-03	Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes MESO GlobeNewswire
Aug-28	Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil MESO -13.29% GlobeNewswire
Aug-27	Mesoblast Financial Results and Corporate Update Webcast MESO GlobeNewswire
Jul-17	Successful Commercial Launch of Ryoncil MESO +26.58% GlobeNewswire
Jun-30	Mesoblast and FDA Align on Key Items for Revascor Biologic License Application in Ischemic Heart Failure MESO +11.29% GlobeNewswire
Jun-11	Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor in Ischemic Heart Failure and Label Extension for Ryoncil in Adults With GvHD MESO GlobeNewswire
May-14	FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil MESO GlobeNewswire

Mesoblast Limited

Recent Articles by Mesoblast Limited

Upgrade your Finviz experience